Print

Purpose

The goal of this clinical study is test how well the study drug, axicabtagene ciloleucel, works in participants with relapsed/refractory follicular lymphoma

Condition

Eligibility

Eligible Ages
Over 18 Years
Eligible Genders
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Histologically-confirmed follicular lymphoma (FL) (Grade 1, 2, or 3a) - Relapsed/refractory (R/r) disease after first-line chemoimmunotherapy and high-risk disease with relapse or progression within 24 months of the initial course of chemoimmunotherapy (ie, POD24), Or r/r disease after ≥ 2 prior systemic lines of therapy - Clinical indication for treatment. - At least 1 measurable lesion per the Lugano Classification {Cheson 2014} - Adequate renal, hepatic, pulmonary, and cardiac function

Exclusion Criteria

  • Presence of large B cell lymphoma or transformed FL - Small lymphocytic lymphoma - Lymphoplasmacytic lymphoma - Full-thickness involvement of the gastric wall by lymphoma - FL Grade 3b - Prior CD19-targeted therapy - Prior CAR therapy or other genetically modified T-cell therapy - Uncontrolled fungal, bacterial, viral, or other infection - Active Infection with human immunodeficiency virus, hepatitis B virus or hepatitis C virus - History or presence of a clincially significant central nervous system (CNS) disorder. - History of autoimmune disease - Known history or CNS lymphoma involvement - Cardiac lymphoma involvement - History of clinically significant cardiac disease 6 months before randomization - Neuropathy greater than grade 2 - Females who are pregnant or breastfeeding - Individuals of both genders who are not willing to practice birth control - Presence of any indwelling line or drain (eg, percutaneous nephrostomy tube, indwelling Foley catheter, biliary drain, G/J-tube, pleural/peritoneal/pericardial catheter, or Ommaya reservoirs). Dedicated central venous access catheters such as Port-a-Cath or Hickman catheter are permitted. Note: Other protocol defined Inclusion/Exclusion criteria may apply.

Study Design

Phase
Phase 3
Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary Purpose
Treatment
Masking
None (Open Label)

Arm Groups

ArmDescriptionAssigned Intervention
Experimental
Axicabtagene Ciloleucel 		Participants will receive cyclophosphamide 500 mg/m^2/day intravenously (IV) and fludarabine 30 mg/m^2/day IV lymphodepleting chemotherapy for 3 days followed by axicabtagene ciloleucel administered as a single IV infusion at a target dose of 2 x 10^6 anti-cluster of differentiation (CD)19 chimeric antigen receptor (CAR) transduced autologous T cells/kg on Day 0. For participants weighing ≥ 100 kg, a maximum flat dose of axicabtagene ciloleucel at 2 x 10^8 anti-CD19 CAR T cells will be administered.
  • Biological: Axicabtagene Ciloleucel
    A single infusion of chimeric antigen receptor (CAR)-transduced autologous T cells
    Other names:
    • Yescarta®
    • axi-cel
  • Drug: Cyclophosphamide
    Administered intravenously
  • Drug: Fludarabine
    Administered intravenously
Active Comparator
Standard of Care Therapy 		Participants will receive the investigator's choice of one of the following therapies/dosing schedules: Rituximab plus lenalidomide (R^2) for 12 cycles (28-day cycle) Cycle 1: lenalidomide 20 mg/day on Day 1 through Day 21; rituximab 375 mg/m^2 on Day 1, Day 8, Day 15, and Day 22 Cycle 2 through Cycle 5: lenalidomide 20 mg/day on Day 1 through Day 21; Rituximab 375 mg/m2 on Day 1 Cycle 6 through Cycle 12: lenalidomide 20 mg/day on Day 1 through Day 21 Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for 6 cycles (21-day cycle) rituximab 375 mg/m^2 on Day 1 cyclophosphamide 750 mg/m^2 on Day 1 doxorubicin 50 mg/m^2 on Day 1 vincristine 1.4 mg/m^2 (maximum 2 mg) on Day 1 prednisone 40 mg/m^2 on Day 1 through Day 5 Rituximab plus bendamustine (BR) for 6 cycles (28-day cycle) rituximab 375 mg/m^2 on Day 1 bendamustine 90 mg/m^2 on Day 1 and Day 2
  • Drug: Cyclophosphamide
    Administered intravenously
  • Drug: Lenalidomide
    Administered orally
  • Drug: Rituximab
    Administered intravenously
  • Drug: Doxorubicin
    Administered intravenously
  • Drug: Vincristine
    Administered intravenously
  • Drug: Prednisone
    Administered orally
  • Drug: Bendamustine
    Administered intravenously

Recruiting Locations

University of Arkansas for Medical Sciences
Little Rock, Arkansas 72205

City of Hope (City of Hope National Medical Center, City of Hope Medical Center)
Duarte, California 91010

UC Irvine Health
Orange, California 92868

Stanford Health Care
Stanford, California 94305

Moffitt Cancer Center
Tampa, Florida 33612

The University of Kansas Hospital
Westwood, Kansas 66205

University of Kentucky Medical Center
Lexington, Kentucky 40536

University of Maryland Greenebaum Comprehensive Cancer Center
Baltimore, Maryland 21201

Dana-Farber Cancer Institute
Boston, Massachusetts 02215

John Theurer Cancer Center at Hackensack University Medical Center
Hackensack, New Jersey 07601

Columbia University Irving Medical Center
New York, New York 10032

Novant Health Cancer Institute Hematology - Charlotte
Charlotte, North Carolina 28204

Oncology_Hematology Care Clinical Trials, LLC
Cincinnati, Ohio 45242

Penn State Milton S. Hershey Medical Center
Hershey, Pennsylvania 17033

UPMC Hillman Cancer Center
Pittsburgh, Pennsylvania 15232

Prisma Health - Upstate
Greenville, South Carolina 29615

Avera Cancer Institute
Sioux Falls, South Dakota 57105

TriStar Centennial Medical Center - Cell Processing
Nashville, Tennessee 37203

The University of Texas MD Anderson Cancer Center
Houston, Texas 77030

Virginia Oncology Associates
Norfolk, Virginia 23502

More Details

NCT ID
NCT05371093
Status
Recruiting
Sponsor
Kite, A Gilead Company

Study Contact

Medical Information
844-454-5483(1-844-454-KITE)
medinfo@kitepharma.com

Detailed Description

Five years after the last study participant is randomized, participants who have received axicabtagene ciloleucel will transition to a separate Long-term Follow-up study (study KT-US-982-5968) to complete the remainder of the 15-year follow-up assessments.

Notice

Study information shown on this site is derived from ClinicalTrials.gov (a public registry operated by the National Institutes of Health). The listing of studies provided is not certain to be all studies for which you might be eligible. Furthermore, study eligibility requirements can be difficult to understand and may change over time, so it is wise to speak with your medical care provider and individual research study teams when making decisions related to participation.